Mavorixafor

Chemical formula: C₂₁H₂₇N₅ Molecular mass: 349.227 g/mol PubChem compound: 11256587

Therapeutic indications

Mavorixafor is indicated for:

WHIM syndrome

Population group: only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Mavorixafor is indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

For patients weighting >50 kg 400 mg once daily and for patients weighting ≤50 kg 300 mg once daily

Contraindications

Mavorixafor is contraindicated in the following cases:

Pregnancy

Lactation

CYP2D6 substrates

Severe renal impairment

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Μoderate hepatic impairment, severe hepatic impairment

at least one of

Hepatic failure stage III
Hepatic failure stage IV

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.